Skip to main content
CMG Pharmaceutical Co., Ltd. logo

CMG Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 058820 ISIN · KR7058820002 KO Manufacturing
Open in API
Filings indexed 165 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 058820

About CMG Pharmaceutical Co., Ltd.

http://www.cmgpharma.co.kr

CMG Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the development of advanced drug delivery systems. The company's core competency is its Oral Thin Film (OTF), or Orally Dissolving Film (ODF), technology platform. This technology is used to develop improved new drugs, new formulations, and combination therapies designed to enhance patient convenience and efficacy. The company's portfolio includes prescription medications and general pharmaceuticals. As an affiliate of CHA Health Systems, CMG Pharmaceutical is actively engaged in research and development, managing a pipeline of drug candidates and conducting clinical trials.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (Quarterly Report) for the 26th fiscal period (2026.01.01–2026.03.31) of CMG제약, and includes actual financial statements, business overview, capital changes, income tables, production data, and managerial analysis. It is a comprehensive quarterly financial report containing substantive data rather than merely announcing or linking to a report. This matches the “Interim / Quarterly Report” definition. Q1 2026
2026-05-14 Korean
전환가액의조정
Share Issue/Capital Change Classification · 85% confidence The document is a Korean regulatory disclosure detailing the adjustment of the conversion price for a tranche of convertible bonds: it lists pre- and post-adjustment conversion prices and share counts, explains the adjustment reason (market price drop) and methodology, and specifies the application date. This is a corporate capital change announcement relating to share issuance upon conversion, matching the “Share Issue/Capital Change” category.
2026-04-13 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled "정기주주총회결과" and contains detailed results of resolutions voted at the 2026-03-27 Annual General Meeting (AGM), including approval of financial statements, election of directors, amendments to charter, and voting percentages for each agenda item. This aligns precisely with the category for official shareholder vote results. Therefore, it should be classified as a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-03-27 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 85% confidence The document is a regulatory submission to the Financial Supervisory Service/Korea Exchange announcing the appointment, reappointment or resignation of an outside (independent) director (“사외이사”). It provides details on the change in board composition. This matches the “Board/Management Information” category for announcements of changes in the company’s board of directors or senior management.
2026-03-27 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for CMG Pharmaceutical Co., Ltd. for the 25th fiscal year (2025). It contains detailed financial statements, management analysis, auditor opinions, and corporate governance information. In the context of South Korean regulatory filings (DART), a 'Business Report' (사업보고서) is the equivalent of an Annual Report (10-K). FY 2025
2026-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing from a Korean company (CMG제약) titled '감사보고서 제출' (Submission of Audit Report). It provides the audit opinion (unqualified/proper), financial highlights (assets, liabilities, equity, revenue, profit/loss), and details regarding the auditor. While it contains financial data, it is a standard regulatory disclosure form used in the Korean market to announce the receipt and submission of the annual audit report to the regulator, rather than the full annual report (10-K) itself. Therefore, it is classified as a regulatory filing. FY 2025
2026-03-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.